Innocan Pharma Corp. Stock
Price
Target price
€0.21
€0.21
-1.400%
-0.003
-1.400%
€1.30
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Innocan Pharma Corp. Stock
A loss of -1.400% shows a downward development for Innocan Pharma Corp..
Innocan Pharma Corp. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
Based on the current price of 0.21 € the target price of 1 € shows a potential of 372.81% for Innocan Pharma Corp. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Innocan Pharma Corp. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Innocan Pharma Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board
Herzliya, Israel and Calgary, Alberta (September 15, 2023) Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology
Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test
- Innocan hair care cream efficacy trial observes enhanced hair growth in male and female participants in a 14day period.
- 91 % of participants reported stronger hair and
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection
Herzliya, Israel and Calgary, Alberta – August 29, 2023 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce the results of a
